KELLY PETERSON: Open Payments
NPI 1770270977 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$634 in 20 payments from 10 companies in 2025. Trend: 2023 $205 · 2024 $803 · 2025 $634
Food & beverage: $634
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 3 | $165 |
| Daiichi Sankyo Inc. | 1 | $127 |
| Amgen Inc. | 5 | $79 |
| PFIZER INC. | 3 | $75 |
| Alnylam Pharmaceuticals Inc. | 2 | $52 |
| Novartis Pharmaceuticals Corporation | 2 | $43 |
| Boston Scientific Corporation | 1 | $31 |
| Merck Sharp & Dohme LLC | 1 | $24 |
| INOGEN, INC. | 1 | $22 |
| ABIOMED | 1 | $17 |
Products named: DATROWAY, Ozempic, Repatha, AMVUTTRA, VYNDAQEL, Wegovy, LEQVIO, WATCHMAN FLX.
Industry payments across NV — which companies pay providers there.
